This company listing is no longer active
0NQA Stock Overview
Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Elanix Biotechnologies AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.07 |
| 52 Week High | €0.07 |
| 52 Week Low | €0.07 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -96.41% |
| Change since IPO | -98.77% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| 0NQA | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 4.0% | 2.7% |
| 1Y | n/a | -23.5% | 5.2% |
Return vs Industry: Insufficient data to determine how 0NQA performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0NQA performed against the UK Market.
Price Volatility
| 0NQA volatility | |
|---|---|
| 0NQA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0NQA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0NQA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Lee-Ann Laurent-Applegate | www.elanixbiotechnologies.ch |
Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care. The company is based in Frankfurt am Main, Germany.
Elanix Biotechnologies AG Fundamentals Summary
| 0NQA fundamental statistics | |
|---|---|
| Market cap | €686.88k |
| Earnings (TTM) | -€4.46m |
| Revenue (TTM) | €280.19k |
0.0x
P/S Ratio0.0x
P/E RatioIs 0NQA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0NQA income statement (TTM) | |
|---|---|
| Revenue | €280.19k |
| Cost of Revenue | €348.59k |
| Gross Profit | -€68.39k |
| Other Expenses | €4.39m |
| Earnings | -€4.46m |
Last Reported Earnings
Jun 30, 2018
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 0NQA perform over the long term?
See historical performance and comparison